Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients

British Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 71-80

  Joerger, M ^a,b   Huitema, A D R ^a   Van Den Bongard, H J G D ^b   Baas, P ^b   Schornagel, J H ^b   Schellens, J H M ^b,c   Beijnen, J H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

7 hydroxy methotrexate; Benzimidazoles; Drug interactions; Methotrexate; NONMEM

Indexed keywords

7 HYDROXYMETHOTREXATE; ASPARAGINASE; BENZIMIDAZOLE DERIVATIVE; BICARBONATE; CISPLATIN; CORTICOSTEROID; DICLOFENAC; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IBUPROFEN; IFOSFAMIDE; LANSOPRAZOLE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; VINCA ALKALOID;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CANCER PATIENT; CANCER THERAPY; CHORIOCARCINOMA; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONLINEAR SYSTEM; OSTEOSARCOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; NEOPLASMS;

EID: 33746871443     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02513.x     Document Type: Article

References (41)

1. Schornagel JH, McVie JG. The clinical pharmacology of methotrexate. Cancer Treat Rev 1983; 10: 53-75.
2. Lankelma JKE, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980; 9: 133-42.
3. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-104.
4. Fuskevag OM, Kristiansen C, Lindal S, Aarbakke J. Maximum tolerated doses of methotrexate and 7-hydroxy-methotrexate in a model of acute toxicity in rats. Cancer Chemother Pharmacol 2000; 46: 69-73.
5. Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxymethotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 1985; 15: 101-4.
6. Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 2002; 38: 1081-9.
7. Bore P, Bruno R, Lena N, Favre R, Cano JP. Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. Eur J Cancer Clin Oncol 1987; 23: 1385-90.
8. Stewart AL, Margison JM, Wilkinson PM, Lucas SB. The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. Cancer Chemother Pharmacol 1985; 14: 165-7.
9. Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol 1985; 12(Suppl 12): 15-20.
10. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986; 1: 256-8.
11. Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E, Koren G. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990; 117: 823-6.
12. Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV, Pla JM. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993; 15: 375-9.
13. Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 1993; 33: 82-4.
14. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002; 302: 666-71.
15. Jansen GHJ, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, Assaraf YG, Dijkmans BA. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2130-9.
16. Smeland E, Bremnes RM, Bessesen A, Jaeger R, Aarbakke J. Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes. Cancer Chemother Pharmacol 1993; 32: 209-14.
17. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 1981; 65(Suppl 4): 115-21.
18. Bruckner HW, Schreiber C, Waxman S. Interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis. Cancer Res 1975; 35: 801-6.
19. Chapter 19. Pharmacology of Cancer Chemotherapy. 19.5: Antimetabolites - Methotrexate: Schedules of Administration. In: de Vita VT, Hellman S, Rosenberg SA, eds. Cancer - Principles and Practice of Oncology. Philadelphia, PA: Lippincott. Williams & Wilkins, 2005.
20. van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67.
21. Favre R, Monjanel S, Alfonsi M, Pradoura JP, Bagarry-Liegey D, Clement S, Imbert AM, Lena N, Colonna DJ, Cano JP, Carcassonne Y. High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance. Cancer Chemother Pharmacol 1982; 9: 156-60.
22. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667-72.
23. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-9.
24. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100: 2222-32.
25. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630-4.
26. Takami M, Kuniyoshi Y, Oomukai T, Ishida T, Yamano Y. Severe complications after high-dose methotrexate treatment. Acta Oncol 1995; 34: 611-2.
27. van Tellingen O, van der Woude HR, Beijnen JH, van Beers CJ, Nooyen WJ. Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids. J Chromatogr 1989; 488: 379-88.
28. Beal SL, Sheiner LB NONMEM. User's Guide. San Francisco: NONMEM Project Group, University of California at San Francisco, 1998.
29. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed 1999; 58: 51-64.
30. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-20.
31. van den Bongard HJGD, Mathot RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH, Beijnen JH. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47: 537-40.
32. Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 1982; 66: 1733- 41.
33. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986; 1: 1390.
34. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34: 1024-7.
35. Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ 2002; 324: 1497.
36. Slordal L, Kolmannskog S, Prytz PS, Moe PJ, Aarbakke J. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. Pediatr Hematol Oncol 1986; 3: 127-34.
37. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994; 37: 453-6.
38. Slordal L, Sager G, Aarbakke J. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet 1988; 1: 591-2.
39. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 5804-11.
40. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15: 277-85.
41. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63: 5538-43.